Aridor, chairman of the board of AEBi and CEO Dr. Ilan Morad, say the AEBi anti-cancer treatment, which they call MuTaTo (multi-target toxin) is essentially on the scale of a cancer antibiotic – a disruption technology of the highest order. They are using peptides. MuTaTo is using a combination of several cancer-targeting peptides for each cancer cell at the same time, combined with a strong peptide toxin that would kill cancer cells specifically. By using at least three targeting peptides on the same structure with a strong toxin, AEBi made sure that the treatment will not be affected by mutations.